Granulomatous Mastitis
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
UNION therapeuticsDenmark - Hellerup
2 programs2
Compound Betamethasone InjectionPhase 41 trial
Hydrocortisone ButyratePhase 41 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
UNION therapeuticsCompound Betamethasone Injection
UNION therapeuticsHydrocortisone Butyrate
Clinical Trials (2)
Total enrollment: 200 patients across 2 trials
Local Steroid Treatment for Idiopathic Granulomatous Mastitis (LSTIGM)
Start: Feb 2019Est. completion: Jan 2022100 patients
Phase 4Unknown
Medical and Surgical Treatment for Idiopathic Granulomatous Mastitis
Start: Jan 2017Est. completion: Sep 2020100 patients
Phase 4Unknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.